Litha’s existing product portfolio comprises nearly 100 molecules focusing on primary care, largely through originator products, and specialty care, partly through generic products.
Through its forensic business, it provides the South African police with DNA evidence collection and crime scene kits. Litha also has a strong pipeline of 124 products that are expected to be launched within the next five years. In addition to this pipeline, Acino plans to complement the portfolio by launching a selection of their existing products in South Africa in the upcoming years.
“We have chosen Litha as they have a strong position in the market and a solid reputation in several therapeutic areas that are strategic for Acino. With its well-established product pipeline and its long-standing relationships with licensing partners, Litha offers very promising prospects for the future,” explains Kalle Känd, CEO of Acino.
“We look forward to joining Acino as we continue to add value to our customers and positively impact patients’ lives. The synergies between the organisations will further support our vision of being one of the top 10 pharma companies in South Africa,” says Guillaume van Niekerk, managing director, Litha Healthcare.
